Figure 1.
Plasma Sdc-1 and sTM in patients on admission and in clinical remission. Plasma levels of Sdc-1 (A) and sTM (B) in patients prior to TPE (Init.) and in clinical remission (Rem.), compared with healthy controls (Con.). Each dot represents an individual patient or control value, and horizontal bars within the dots represent the median and IQR. Kruskal-Wallis test corrected with Dunn’s multiple comparisons was performed to determine statistical significance. Longitudinal changes in plasma levels of Sdc-1 (C) and sTM (D) in paired individual patients prior to TPE (Initi., blue dots) and in clinical response/remission (Remi., red dots). A Wilcoxon matched-pairs signal test (2 tailed and nonparametric) was used to determine statistical significance. P > .05 (n.s., not significant); *P < .05; ****P < .0001.

Plasma Sdc-1 and sTM in patients on admission and in clinical remission. Plasma levels of Sdc-1 (A) and sTM (B) in patients prior to TPE (Init.) and in clinical remission (Rem.), compared with healthy controls (Con.). Each dot represents an individual patient or control value, and horizontal bars within the dots represent the median and IQR. Kruskal-Wallis test corrected with Dunn’s multiple comparisons was performed to determine statistical significance. Longitudinal changes in plasma levels of Sdc-1 (C) and sTM (D) in paired individual patients prior to TPE (Initi., blue dots) and in clinical response/remission (Remi., red dots). A Wilcoxon matched-pairs signal test (2 tailed and nonparametric) was used to determine statistical significance. P > .05 (n.s., not significant); *P < .05; ****P < .0001.

Close Modal

or Create an Account

Close Modal
Close Modal